LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

Home・Aktien・Novo Nordisk A-S

Novo Nordisk A-S

Geschlossen

Branche Gesundheitswesen

112.01 -0.39

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

111.12

Max

113.16

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5.4B 20B
Verkäufe	2.7B 68B
KGV Branchendurchschnitt	49.94 112.16
EPS	4.49
Gewinnspanne	29.459
EBITDA	-1.2B 36B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+37.28 upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.4B 396B
Vorheriger Eröffnungskurs	112.4
Vorheriger Schlusskurs	112.01

Nachrichtenstimmung

By Acuity

45%

55%

169 / 389 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

N/A / 117.81 Unterstützung & Widerstand

Novo Nordisk A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Sept. 2024, 19:26 UTC

Wichtige Markttreiber

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

26. Okt. 2024, 11:00 UTC

Top News

Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ

25. Okt. 2024, 09:30 UTC

Top News

Big Food Is Learning to Love Weight-Loss Drugs -- Heard on the Street -- WSJ

4. Okt. 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking -2-

4. Okt. 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

3. Okt. 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 13:12 UTC

Top News

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 12:51 UTC

Market Talk

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2. Okt. 2024, 13:48 UTC

Ergebnisse

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2. Okt. 2024, 12:28 UTC

Market Talk

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2. Okt. 2024, 09:00 UTC

Market Talk

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

26. Sept. 2024, 13:15 UTC

Market Talk

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

26. Sept. 2024, 11:51 UTC

Market Talk

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

23. Sept. 2024, 10:37 UTC

Top News

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

23. Sept. 2024, 10:37 UTC

Top News

Fed Uncertainty Is History. Now Markets Need to -2-

20. Sept. 2024, 16:30 UTC

Market Talk

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

20. Sept. 2024, 13:55 UTC

Top News

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20. Sept. 2024, 12:46 UTC

Top News

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20. Sept. 2024, 09:30 UTC

Top News

The Price War in Weight-Loss Drugs Is Here -- WSJ

12. Sept. 2024, 13:00 UTC

Top News

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12. Sept. 2024, 11:45 UTC

Market Talk

Ergebnisse

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12. Sept. 2024, 10:30 UTC

Market Talk

Ergebnisse

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11. Sept. 2024, 12:08 UTC

Top News

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9. Sept. 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3. Sept. 2024, 11:09 UTC

Top News

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27. Aug. 2024, 05:30 UTC

Top News

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14. Aug. 2024, 12:01 UTC

Market Talk

Ergebnisse

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9. Aug. 2024, 11:30 UTC

Top News

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9. Aug. 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8. Aug. 2024, 15:44 UTC

Top News

Ergebnisse

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S Prognose

Kursziel

By TipRanks

37.28% Vorteil

12-Monats-Prognose

Durchschnitt 154.25 USD 37.28%

Hoch 160 USD

Tief 146 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Novo Nordisk A-S – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 117.81Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

169 / 389 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.